139 related articles for article (PubMed ID: 27045477)
1. Rare ATAD5 missense variants in breast and ovarian cancer patients.
Maleva Kostovska I; Wang J; Bogdanova N; Schürmann P; Bhuju S; Geffers R; Dürst M; Liebrich C; Klapdor R; Christiansen H; Park-Simon TW; Hillemanns P; Plaseska-Karanfilska D; Dörk T
Cancer Lett; 2016 Jun; 376(1):173-7. PubMed ID: 27045477
[TBL] [Abstract][Full Text] [Related]
2. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
[TBL] [Abstract][Full Text] [Related]
3. A targeted genetic association study of epithelial ovarian cancer susceptibility.
Earp M; Winham SJ; Larson N; Permuth JB; Sicotte H; Chien J; Anton-Culver H; Bandera EV; Berchuck A; Cook LS; Cramer D; Doherty JA; Goodman MT; Levine DA; Monteiro AN; Ness RB; Pearce CL; Rossing MA; Tworoger SS; Wentzensen N; Bisogna M; Brinton L; Brooks-Wilson A; Carney ME; Cunningham JM; Edwards RP; Fogarty ZC; Iversen ES; Kraft P; Larson MC; Le ND; Lin HY; Lissowska J; Modugno F; Moysich KB; Olson SH; Pike MC; Poole EM; Rider DN; Terry KL; Thompson PJ; van den Berg D; Vierkant RA; Vitonis AF; Wilkens LR; Wu AH; Yang HP; Ziogas A; Phelan CM; Schildkraut JM; Chen YA; Sellers TA; Fridley BL; Goode EL
Oncotarget; 2016 Feb; 7(7):7381-9. PubMed ID: 26848776
[TBL] [Abstract][Full Text] [Related]
4. Rare
Moyer CL; Ivanovich J; Gillespie JL; Doberstein R; Radke MR; Richardson ME; Kaufmann SH; Swisher EM; Goodfellow PJ
Cancer Res; 2020 Feb; 80(4):857-867. PubMed ID: 31822495
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach.
Ab Mutalib NS; Syafruddin SE; Md Zain RR; Mohd Dali AZ; Mohd Yunos RI; Saidin S; Jamal R; Mokhtar NM
BMC Res Notes; 2014 Nov; 7():805. PubMed ID: 25404506
[TBL] [Abstract][Full Text] [Related]
6. Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer.
Jønson L; Ahlborn LB; Steffensen AY; Djursby M; Ejlertsen B; Timshel S; Nielsen FC; Gerdes AM; Hansen TV
Breast Cancer Res Treat; 2016 Jan; 155(2):215-22. PubMed ID: 26740214
[TBL] [Abstract][Full Text] [Related]
7. Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer.
Paulo P; Maia S; Pinto C; Pinto P; Monteiro A; Peixoto A; Teixeira MR
PLoS Genet; 2018 Apr; 14(4):e1007355. PubMed ID: 29659569
[TBL] [Abstract][Full Text] [Related]
8. Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan.
Rashid MU; Muhammad N; Faisal S; Amin A; Hamann U
Breast Cancer Res Treat; 2014 Jun; 145(3):775-84. PubMed ID: 24800917
[TBL] [Abstract][Full Text] [Related]
9. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
[TBL] [Abstract][Full Text] [Related]
10. Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer.
Li N; McInerny S; Zethoven M; Cheasley D; Lim BWX; Rowley SM; Devereux L; Grewal N; Ahmadloo S; Byrne D; Lee JEA; Li J; Fox SB; John T; Antill Y; Gorringe KL; James PA; Campbell IG
J Natl Cancer Inst; 2019 Dec; 111(12):1332-1338. PubMed ID: 30949688
[TBL] [Abstract][Full Text] [Related]
11. RAD51C mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families.
Krivokuca A; Yanowski K; Rakobradovic J; Benitez J; Brankovic-Magic M
Cancer Biomark; 2015; 15(6):775-81. PubMed ID: 26406419
[TBL] [Abstract][Full Text] [Related]
12. Integrated microRNA and mRNA signatures in peripheral blood lymphocytes of familial epithelial ovarian cancer.
Dou YD; Huang T; Wang Q; Shu X; Zhao SG; Li L; Liu T; Lu G; Chan WY; Liu HB
Biochem Biophys Res Commun; 2018 Jan; 496(1):191-198. PubMed ID: 29307835
[TBL] [Abstract][Full Text] [Related]
13. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Ramalingam P
Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
[TBL] [Abstract][Full Text] [Related]
14. Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.
Spugnesi L; Gabriele M; Scarpitta R; Tancredi M; Maresca L; Gambino G; Collavoli A; Aretini P; Bertolini I; Salvadori B; Landucci E; Fontana A; Rossetti E; Roncella M; Naccarato GA; Caligo MA
Genes Chromosomes Cancer; 2016 Dec; 55(12):915-924. PubMed ID: 27328445
[TBL] [Abstract][Full Text] [Related]
15. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
16. Predisposition to cancer caused by genetic and functional defects of mammalian Atad5.
Bell DW; Sikdar N; Lee KY; Price JC; Chatterjee R; Park HD; Fox J; Ishiai M; Rudd ML; Pollock LM; Fogoros SK; Mohamed H; Hanigan CL; ; Zhang S; Cruz P; Renaud G; Hansen NF; Cherukuri PF; Borate B; McManus KJ; Stoepel J; Sipahimalani P; Godwin AK; Sgroi DC; Merino MJ; Elliot G; Elkahloun A; Vinson C; Takata M; Mullikin JC; Wolfsberg TG; Hieter P; Lim DS; Myung K
PLoS Genet; 2011 Aug; 7(8):e1002245. PubMed ID: 21901109
[TBL] [Abstract][Full Text] [Related]
17. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U
BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291
[TBL] [Abstract][Full Text] [Related]
18. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.
Guerini-Rocco E; Piscuoglio S; Ng CK; Geyer FC; De Filippo MR; Eberle CA; Akram M; Fusco N; Ichihara S; Sakr RA; Yatabe Y; Vincent-Salomon A; Rakha EA; Ellis IO; Wen YH; Weigelt B; Schnitt SJ; Reis-Filho JS
J Pathol; 2016 Apr; 238(5):677-88. PubMed ID: 26806567
[TBL] [Abstract][Full Text] [Related]
19. RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer.
Häfner N; Steinbach D; Jansen L; Diebolder H; Dürst M; Runnebaum IB
Int J Cancer; 2016 Jan; 138(1):217-28. PubMed ID: 26175272
[TBL] [Abstract][Full Text] [Related]
20. Germline mutations in RAD51C in Jewish high cancer risk families.
Kushnir A; Laitman Y; Shimon SP; Berger R; Friedman E
Breast Cancer Res Treat; 2012 Dec; 136(3):869-74. PubMed ID: 23117857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
